GENE חוב כולל להון GTG Labs

The growth of Genetic Technologies (GENE) relies on recognition by insurance structures and the legalization of preventive diagnostics. This daily price chart from GURU.Markets shows the metric at 0.48, which is attributed to a profit deficit and the expenditure of capital on molecular research. However, the implementation of cloud AI for mass screening will allow for a manifold reduction in genome processing costs, ensuring high business scalability.

The leverage dynamics reflect the financial stability of Genetic Technologies as it scales predictive genetic testing and integrates PRS analysis into medicine. This ratio is calculated as total liabilities to equity, allowing investors to assess the business's dependence on borrowed funds and determine the balance between high leverage risk and capital efficiency.